Literature DB >> 23942944

Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study.

Francesco Cantiello1, Antonio Cicione, Riccardo Autorino, Andrea Salonia, Alberto Briganti, Matteo Ferro, Renato De Domenico, Sisto Perdonà, Rocco Damiano.   

Abstract

PURPOSE: To evaluate the pathological characteristics of patients with metabolic syndrome (MetS) undergoing radical cystectomy (RC) for urothelial bladder cancer (BCa).
METHODS: We retrospectively analyzed 262 consecutive patients with muscle-invasive urothelial BCa or non-muscle-invasive urothelial BCa bacillus Calmette-Guerin refractory undergoing RC with standard pelvic lymphadenectomy. The patients were stratified into those with or without MetS, and a bivariate logistic regression analysis was done to assess MetS and, separately, each single MetS component as independent predictors of higher pathological stage as well as of the presence of lymph vascular invasion (LVI) and lymph node metastasis (LM).
RESULTS: Metabolic syndrome was found in 36.3 % of patients. At logistic regression analysis, the presence of MetS did not predict the risk of both higher pathological stage and LVI and LM. Investigating the single components of MetS after adjusting for age, gender, and smoking, the risk of higher pathological stage increased with body mass index [BMI (OR 1.307, 95 % CI 1.098-1.555)], waist circumference (OR 1.414, 95 % CI 1.364-1.668), and blood hypertension (OR 2.326, 95 % CI 1.147-4.717). Higher BMI also predicted the presence of LVI (OR 1.432, 95 % CI 1.173-1.748) and LM (OR 1.202, 95 % CI 0.951-1.519), whereas HDL cholesterol was inversely associated with the risk of LVI and LM.
CONCLUSIONS: Metabolic syndrome does not represent an independent risk factor for worse pathological findings in BCa. Conversely, individual components of MetS could increase the risk of higher stage as well as LM.

Entities:  

Mesh:

Year:  2013        PMID: 23942944     DOI: 10.1007/s00345-013-1147-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  29 in total

1.  Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients.

Authors:  Takafumi Tamura; Satoshi Inagawa; Katsuji Hisakura; Tsuyoshi Enomoto; Nobuhiro Ohkohchi
Journal:  J Gastroenterol Hepatol       Date:  2012-10       Impact factor: 4.029

2.  Diabetes mellitus and risk of bladder cancer: a meta-analysis.

Authors:  S C Larsson; N Orsini; K Brismar; A Wolk
Journal:  Diabetologia       Date:  2006-10-05       Impact factor: 10.122

3.  Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy.

Authors:  Cosimo De Nunzio; Stephen J Freedland; Roberto Miano; Alberto Trucchi; Andrea Cantiani; Alfonso Carluccini; Andrea Tubaro
Journal:  Prostate       Date:  2011-02-25       Impact factor: 4.104

4.  Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study.

Authors:  Hassan Abol-Enein; Derya Tilki; Ahmed Mosbah; Mahmoud El-Baz; Ahmed Shokeir; Adel Nabeeh; Mohamed A Ghoneim
Journal:  Eur Urol       Date:  2011-06-12       Impact factor: 20.096

5.  Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can).

Authors:  Christel Häggström; Tanja Stocks; Kilian Rapp; Tone Bjørge; Björn Lindkvist; Hans Concin; Anders Engeland; Jonas Manjer; Hanno Ulmer; Randi Selmer; Steinar Tretli; Göran Hallmans; Håkan Jonsson; Pär Stattin
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

6.  Prevalence of the metabolic syndrome among Italian adults according to ATP III definition.

Authors:  Roberto Miccoli; Cristina Bianchi; Leonardo Odoguardi; Giuseppe Penno; Francesco Caricato; Maria Giovanna Giovannitti; Laura Pucci; Stefano Del Prato
Journal:  Nutr Metab Cardiovasc Dis       Date:  2005-08       Impact factor: 4.222

7.  The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.

Authors:  Jonathan L Wright; Daniel W Lin; Michael P Porter
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

8.  Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.

Authors:  John K Ninomiya; Gilbert L'Italien; Michael H Criqui; Joanna L Whyte; Anthony Gamst; Roland S Chen
Journal:  Circulation       Date:  2003-12-15       Impact factor: 29.690

Review 9.  Insulin, insulin-like growth factors, insulin resistance, and neoplasia.

Authors:  Michael N Pollack
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

10.  Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy.

Authors:  Kyoung Pil Jeon; Tae Yoong Jeong; Seo Yeon Lee; Sang Won Hwang; Joong Hui Shin; Dong Suk Kim
Journal:  Korean J Urol       Date:  2012-09-19
View more
  10 in total

1.  Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer.

Authors:  Tianyuan Xu; Zhaowei Zhu; Xianjin Wang; Leilei Xia; Xiaohua Zhang; Shan Zhong; Fukang Sun; Yu Zhu; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2015-05-26       Impact factor: 2.370

2.  Early or Delayed Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Hard Dilemma to Solve.

Authors:  Cosimo De Nunzio; Riccardo Lombardo; Antonio Cicione
Journal:  Eur Urol Open Sci       Date:  2022-06-16

3.  Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.

Authors:  Radosław Piliszek; Anna A Brożyna; Witold R Rudnicki
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

Review 4.  Obesity, Physical Activity and Bladder Cancer.

Authors:  Jonathan L Noguchi; Michael A Liss; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2015-10       Impact factor: 3.092

5.  Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study.

Authors:  Maurizio Montella; Matteo Di Maso; Anna Crispo; Maria Grimaldi; Cristina Bosetti; Federica Turati; Aldo Giudice; Massimo Libra; Diego Serraino; Carlo La Vecchia; Rosa Tambaro; Ernesta Cavalcanti; Gennaro Ciliberto; Jerry Polesel
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

Review 6.  Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.

Authors:  Chunyu Zhang; Jiao Hu; Huihuang Li; Hongzhi Ma; Belaydi Othmane; Wenbiao Ren; Zhenglin Yi; Dongxu Qiu; Zhenyu Ou; Jinbo Chen; Xiongbing Zu
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

7.  Association of metabolic syndrome and the risk of bladder cancer: A prospective cohort study.

Authors:  Shuo Fang; Yuchen Liu; Huiru Dai; Tianshun Gao; Leli Zeng; Rui Sun; Zilong Zheng; Jinqiu Yuan; Bin Xia; Yihang Pan
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

8.  The association between metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study in China.

Authors:  Sheng Xu; Gui-Ming Zhang; Feng-Ju Guan; Da-Hai Dong; Lei Luo; Bin Li; Xiao-Cheng Ma; Jun Zhao; Li-Jiang Sun
Journal:  World J Surg Oncol       Date:  2015-08-07       Impact factor: 2.754

9.  Estimating the impact of body mass index on bladder cancer risk: Stratification by smoking status.

Authors:  Jin Bong Choi; Eun Joo Lee; Kyung-Do Han; Sung-Hoo Hong; U-Syn Ha
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

10.  Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.

Authors:  Hyeong Dong Yuk; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Kyung Chul Moon; Ja Hyeon Ku
Journal:  BMC Cancer       Date:  2019-09-09       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.